For the Inventor, By the Inventor

Enter assignee name

Stallergenes

USPTO Granted Patents = 13

CIPO Patents = 1

EPO Patents = 14

Trademarks = 4

Forward Citations = 7

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Philippe Moingeon (12 out of 14 patents)

Emmanuel Nony (6 out of 29 patents)

Laurent Mascarell (4 out of 5 patents)

4. Véronique Bodo (4 out of 4 patents)

5. Julien Bouley (4 out of 4 patents)

6. Thierry Batard (3 out of 5 patents)

7. Laurence Van Overtvelt (3 out of 3 patents)

8. Alain Razafindratsita (3 out of 3 patents)

9. Bertrand Villet (2 out of 2 patents)

10. Vincent Lombardi (2 out of 2 patents)

11. Claire Gueguen (2 out of 2 patents)

12. Sophie Tourdot (2 out of 2 patents)

13. Aline Zimmer (2 out of 3 patents)

14. Noémie Caillot (1 out of 2 patents)

15. Hélène Moussu (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 11028441 - IL-10 as a predictive biomarker of responsiveness to house dust mite allergen immunotherapy (2021-06-08),

2. 11027010 - Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids (2021-06-08),

3. 11015221 - Markers of immune response (2021-05-25),

4. 10884002 - Sialylated fetuin-A as a marker of immunotherapy efficacy (2021-01-05),

5. 10610586 - Compositions for antigen-specific induction of tolerance (2020-04-07),

6. 10190166 - Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy (2019-01-29),

7. 10101341 - Biomarkers of immunotherapy efficacy (2018-10-16),

8. 9868770 - Recombinant Der P 2 expressed in Pichia Pastoris as a 'natural-like' allergen for immunotherapy and diagnostic purposes (2018-01-16),

9. 9822185 - Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa (2017-11-21),

10. 9795644 - Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids (2017-10-24),

11. 9555102 - Compositions for antigen-specific induction of tolerance (2017-01-31),

12. 9480748 - Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance (2016-11-01),

13. 7285650 - [object Object] (2007-10-23),

STALLERGENES GREER is a global biopharmaceutical company specialized in the diagnosis and treatment of allergies. With more than 60 years of experience, Stallergenes offers a range of innovative products and services to improve the lives of allergy patients worldwide. The company is committed to providing high-quality diagnostic tools and immunotherapy treatments for various allergies, such as respiratory allergies originating from pollen, mites, pets, and more. Stallergenes Greer operates in numerous countries, collaborating with healthcare professionals and patients to address the rising global burden of allergies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

13 Patents

#7 in Antony

#1,369 in France

#43,690 in the World

Stallergenes

Forward Citations = 7

25 inventors:

Philippe Moingeon (12 out of 14 patents)

Emmanuel Nony (6 out of 29 patents)

Laurent Mascarell (4 out of 5 patents)

4. Véronique Bodo (4 out of 4 patents)

5. Julien Bouley (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…